|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
A genetic association exists between DRD1 gene and impaired cognition in BD.
|
25233244 |
2015 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
A genetic association exists between DRD1 gene and impaired cognition in BD.
|
25233244 |
2015 |
|
Bipolar Disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Patients with affective disorders showed an opposite pattern: reduced expression of D2S (major depressive disorder, P<0.0001) and increased expression of D2L and DRD1 (bipolar disorder, P<0.0001).
|
24322206 |
2014 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Patients with affective disorders showed an opposite pattern: reduced expression of D2S (major depressive disorder, P<0.0001) and increased expression of D2L and DRD1 (bipolar disorder, P<0.0001).
|
24322206 |
2014 |
|
Bipolar Disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Vitamin D receptor FokI genotype may modify the susceptibility to schizophrenia and bipolar mood disorder by regulation of dopamine D1 receptor gene expression.
|
23042374 |
2012 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Vitamin D receptor FokI genotype may modify the susceptibility to schizophrenia and bipolar mood disorder by regulation of dopamine D1 receptor gene expression.
|
23042374 |
2012 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Here we compare gene expression levels for 17 genes [including all 11 dopamine receptor interacting proteins, all 5 dopamine receptors (DRD1-DRD5) and DARPP-32] by real-time polymerase chain reaction, using prefrontal cortex post mortem brain samples from 33 schizophrenic, 32 bipolar disorder and 34 control subjects.
|
20874815 |
2011 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Polymorphisms within the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes are being studied for association with lithium prophylaxis in a sample of 155 Sardinian unrelated probands affected by bipolar disorder (BP).
|
19647327 |
2009 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
CTD_human |
Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder.
|
19153942 |
2009 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genetic association between three DRD1 single nucleotide polymorphisms (SNPs) (-800T/C, -48A/G, and 1403T/C) and bipolar type I (BP I) disorder was performed in a case-control sample of Sardinian origin (170 BP I and 209 controls) and in an enlarged sample (229 families) of BP I trios from Toronto.
|
17066478 |
2007 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
These data suggest that the -48A/G polymorphism of the DRD1 gene may be involved in the etiology of bipolar disorder in a Polish population.
|
16397404 |
2006 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that the -48A/G polymorphism of the DRD1 gene may be involved in the etiology of bipolar disorder in a Polish population.
|
16397404 |
2006 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
In line with a considerable amount of evidence, the dopamine D1 receptor gene (DRD1) is considered to be a good candidate gene for bipolar disorders.
|
15704231 |
2005 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
There is also growing evidence for the role of DRD1, NMDA receptor genes (GRIN1, GRIN2A, GRIN2B), brain-derived neurotrophic factor (BDNF), and dopamine transporter (SLC6A3) in both schizophrenia and bipolar disorder.
|
15952869 |
2005 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Based on the dopamine hypothesis, the dopamine D1 receptor gene (DRD1) is considered to be a good candidate gene for bipolar disorder (BP).
|
12488059 |
2002 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Allele frequencies were similar in patients and controls, indicating that genetic variation in the 5'-regulatory region of the DRD1 gene is unlikely to play a frequent, major role in the genetic predisposition to either schizophrenia or bipolar affective disorder.
|
8837716 |
1996 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Linkage of bipolar disorder and recurrent depression to DRD1 and DRD2 was tested using a series of genetic models with varying penetrance levels.
|
1385598 |
1992 |
|
Parkinson Disease
|
0.570 |
Biomarker
|
disease |
BEFREE |
Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
|
31626851 |
2020 |
|
Parkinson Disease
|
0.570 |
Biomarker
|
disease |
BEFREE |
Pharmacological agonism of D1 receptor exerts anxiolytic and antidepressant-like effects as well as enhanced NSC proliferation, long-term survival and neuronal differentiation by positively regulating Wnt/β-catenin signaling pathway in hippocampus in PD rats. shRNA lentivirus mediated knockdown of Axin-2, a negative regulator of Wnt/β-catenin signaling potentially attenuated D1 receptor antagonist induced anxiety and depression-like phenotypes and impairment in adult hippocampal neurogenesis in PD rats.
|
30500462 |
2019 |
|
Parkinson Disease
|
0.570 |
GeneticVariation
|
disease |
BEFREE |
Parkinson's disease (PD) patients are usually treated with L-dopa and/or dopaminergic agonists, which act by binding five types of dopaminergic receptors (DRD1-DRD5).
|
31311029 |
2019 |
|
Parkinson Disease
|
0.570 |
Biomarker
|
disease |
BEFREE |
This was a Phase I, double-blind clinical trial assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of the novel dopamine D1 receptor partial agonist, PF-06669571, in subjects with idiopathic Parkinson's disease on a stable dose of L-DOPA.
|
29478239 |
2018 |
|
Parkinson Disease
|
0.570 |
GeneticVariation
|
disease |
BEFREE |
These results demonstrate that VPS35 regulates DRD1 trafficking and DRD1-mediated dopamine signaling pathway, and that the PD-associated VPS35 (D620N) mutant loses such functions, providing a novel molecular mechanism underlying PD pathogenesis.
|
27460146 |
2016 |
|
Parkinson Disease
|
0.570 |
GeneticVariation
|
disease |
BEFREE |
We have chosen PD relevant promoter candidates for gene therapy vectors based on either previous studies; Drd1a, Drd2 and pDyn, or from a microarray study on parkinsonian patients; ACE, DNAJC3, GALNS, MAP1a and RNF25.
|
23063686 |
2012 |
|
Parkinson Disease
|
0.570 |
Therapeutic
|
disease |
RGD |
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking.
|
23041629 |
2012 |
|
Parkinson Disease
|
0.570 |
Biomarker
|
disease |
RGD |
Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat.
|
16365282 |
2006 |